Official: Joint Iran-Cuba Vaccine Fully Efficient against New Variant of COVID-19

Head of Pasteur Institute of Iran Alireza Biglari said that the coronavirus vaccine jointly produced by Iran and Cuba has proved totally efficient in preventing infection to the new variant of the virus, Omicron.

Pasteurcovac vaccine, jointly developed by Iran and Cuba, has proved to be 100% effective against Omicron variant of the COVID-19, Biglari told reporters via videoconference on Saturday.

He said that Pasteurcovac is permitted to be injected to children and adults.

He described Pasteurcovac as the safest vaccine against coronavirus, saying it had been tested against Beta Variant in Cuba and against Delta Variant in Iran and had been proved to be 96% effective.

Biglari went on to say that five million doses of Pasteurcovac vaccine is produced monthly in Iran and two doses are enough for children.

He also stressed that adults should receive booster dose, adding that Pasteurcovac can be used as booster for all vaccines.

Pasteurcovac, known as Soberana 2 in Cuba, has jointly been developed by Iran and Cuba and successfully passed the third phase for clinical test.